A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
Status:
Not yet recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the response of glucagon to insulin-induced low
blood sugar after administration of the study drug LY3532226 in participants with type 1
diabetes mellitus (T1DM). The study will also evaluate if LY3532226 helped participants to
recover from insulin-induced low blood sugar condition compared to placebo. The study will
last approximately 16 weeks excluding screening period.